Cadila Healthcare has entered into a manufacturing license and technology transfer agreement for its Plasmid DNA based Covid-19 (ZyCoV-D) vaccine with Enzychem Lifesciences (Enzychem) of Republic of Korea. The company will provide manufacturing license and transfer the Plasmid DNA vaccine technology to Enzychem Lifesciences. Both Cadila Healthcare and Enzychem believe that this partnership will lead to an estimated manufacturing of 80 million or more doses of the Plasmid DNA vaccine in 2022.
Under the agreement, Enzychem will manufacture and commercialise the vaccine within its territory under a Zydus trademark and Cadila Healthcare will receive the license fees and royalty payments for the same. ZyCoV-D is the first DNA plasmid vaccine in the world for human use, developed indigenously by Cadila Healthcare against the Covid-19 virus. The vaccine is administered intradermally using the PharmaJet needle free applicator, which ensures painless intradermal vaccine delivery.
Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.
